Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention by Hoppe, Bernd & Leumann, Ernst
Nephrol Dial Transplant (2004) 19: 39–42
DOI: 10.1093/ndt/gfg507
Child–Adult Interface
Diagnostic and therapeutic strategies in hyperoxaluria:
a plea for early intervention
Bernd Hoppe1 and Ernst Leumann2
1University Children’s Hospital, Division of Paediatric Nephrology, University of Cologne, Germany and
2University Children’s Hospital, Division of Paediatric Nephrology, Zurich, Switzerland
Keywords: diagnosis; primary hyperoxaluria; second-
ary hyperoxaluria; transplantation; treatment
Introduction
Oxalic acid is an end product of human metabolism
and does not appear to be needed for any process in
the body. Under normal conditions the daily load of
oxalate deriving from endogenous production and
intestinal absorption is fully excreted by the kidneys.
Up to a certain extent renal oxalate excretion may even
keep pace with an elevated oxalate load, yet at the
expense of hyperoxaluria, a major risk factor for
recurrent nephrolithiasis and nephrocalcinosis [1,2].
Unfortunately, hyperoxaluria is all too often over-
looked at this stage. The situation becomes far more
serious if renal function is impaired (e.g. from
complications of hyperoxaluria): the amount of oxalate
excreted in the urine will no longer match its produc-
tion and absorption, resulting in progressive oxalate
retention with renal and extrarenal deposition of
calcium oxalate, i.e. systemic oxalosis [3]. In a recent
survey from the US 30% of patients with primary
hyperoxaluria (PH) were only diagnosed after having
reached end-stage renal failure (ESRF [4]). Late
diagnosis is a particular problem in adult patients. In
a recent Dutch study, 59% of those patients older than
18 years had already reached ESRF at the time of
diagnosis of PH I [5].
Two forms of autosomal-recessive inherited PHs
have been characterized at the molecular level, both
being due to defects of glyoxylate metabolism [6–8].
One or several other types of PH are likely to exist, and
there is a certain overlap with severe forms of secondary
hyperoxaluria [9,10].
Diagnosis
The hallmark of type I and II PH is a strongly eleva-
ted urinary excretion of oxalate (>1mmol/1.73m2
BSA/day, normal <0.5) [1]. Urinary oxalate excre-
tion in secondary hyperoxaluria is usually <1.0mmol/
1.73m2 BSA/day [2] (Figure 1). Urinary oxalate over
creatinine ratios may be used for screening in children
as long as age-speciﬁc normal values (for age <2 years,
<300; for age 2–5 years, <130; for age 5–15 years,
<70 and for age >16 years, <40mmol/mol) are at
hand [11]. However, the ratios need to be conﬁrmed by
complete urine collection. Urinary glycolate excretion
is elevated in most patients with PH I, whereas urinary
L-glyceric acid excretion is increased in nearly all
patients with PH II. Hence, isolated hyperoxaluria
does not exclude with certainty either type of PH.
On the other hand, hyperoxaluria plus elevated excre-
tion of either glycolate or L-glyceric acid is a strong
argument but no proof for this diagnosis (PH I or PH
II) [9,10].
Caution is needed in the interpretation of urinary
values in recurrent stone formers who are not stone free
at the time of urine collection, as calcium and oxalate
are deposited continuously, leading to ongoing stone
growth and hence to a lower urinary excretion [12].
On the other hand, a high oxalate diet (e.g. spinach,
rhubarb juice, etc.) on the day of urine collection must
be avoided, as it would deﬁnitively increase the urinary
oxalate levels.
The ﬁnding of pure CaOxmono-hydrate (whewellite)
stones is a hint to the diagnosis of PH. Stones of
patients with secondary hyperoxaluria are usually
mixed (whewellite and weddellite) [10,13].
Values of urinary oxalate are falsely low in patients
with renal insufﬁciency because of oxalate retention
and systemic deposition as calcium oxalate, hence
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hyperoxaluria may be missed. Determination of plasma
oxalate (POx) can help in this situation. Normal levels of
POx range from 0.5 to 7.5 mmol/l depending on the
method used [1,14], with 10 mmol/l being the upper
cut-off point in our lab. The increase of POx is inversely
correlated with the fall of GFR, being signiﬁcantly
higher in PH patients, compared with non-PH patients
in renal insufﬁciency [15].
Data of urinary oxalate in ESRF cannot be used in
contrast to plasma levels of oxalate and glycolate
[16]. Patients with PH have signiﬁcantly higher POx
levels (>80 mmol/l) than non-PH patients in ESRF
(<60 mmol/l) [17]. Plasma glycolate levels are signiﬁ-
cantly elevated in PH I patients only once they are on
renal replacement therapy [16]. The ﬁnding of bire-
fringent CaOx crystals at a bone or kidney biopsy is
strongly suggestive of PH, and an eye ground
examination showing crystal retinopathy is virtually
diagnostic [1].
Liver biopsy for enzymatic analysis is needed for
deﬁnitive diagnosis if liver transplantation is con-
sidered, unless the genotype is known or diagnosis
has been conﬁrmed in a sibling. DNA analysis as
a diagnostic procedure is not a standard technique
except in populations with a high frequency of a speciﬁc
mutation [1,18].
If these diagnostic procedures do not yield a
deﬁnitive diagnosis, further evaluation is recommended
before speciﬁc therapy is started. Another recently
reported cause of signiﬁcant secondary hyperoxaluria is
the absence of oxalate degrading bacteria such as
Oxalobacter formigenes and, allegedly, other species
(Enterococcus faecalis, Eubacterium lentum and lactic
acid bacteria) in the gut [19–21]. The obligate anaerobe
bacterium O.formigenes degrades oxalate to formiate,
which is further metabolized and excreted via the faeces
[2,19]. It is found in the intestinal tract in the majority
of the adult population (70–80%) and protects them
from increased intestinal oxalate absorption and
ensuing hyperoxaluria. Identiﬁcation of Oxalobacter
in stool samples is possible with the PCR technique.
Recurrent calcium oxalate stone formers and patients
with malabsorption syndromes or patients with hyper-
oxaluria of unknown origin often lack Oxalobacter.
This might be due to antibiotic treatment (e.g. in
patients with cystic ﬁbrosis), or to speciﬁc therapy of
the underlying disease (e.g. in Crohn’s disease) [2,22].
Increased intestinal oxalate absorption can be assessed
by an absorption test using [13C2]oxalate [23]. It helps
to identify hyperabsorbers, who need speciﬁc therapy
(e.g. low oxalate, high calcium diet), and to differentiate
between primary and secondary forms of hyperoxa-
luria. It is easy to perform and without risks, as the
isotope used is stable.
Conservative treatment
Measures to lower the oxalate load
Primary hyperoxaluria. Pyridoxal phosphate is an
essential cofactor of AGT and pharmacological doses
of pyridoxine may signiﬁcantly reduce hyperoxaluria.
About one-third of PH I patients are pyridoxine
sensitive [1]. Pyridoxine is started with 5mg/kg body
weight/day and is stepwise increased up to 20mg/kg
day, in order to exclude or demonstrate pyridoxine
responsiveness (>30% reduction). A trial over some
months is warranted in all PH I patients.
Secondary hyperoxaluria. A dietary advice is neces-
sary (high calcium, low oxalate diet). The use of oxalate
degrading bacteria like Oxalobacter to reduce the
amount of oxalate available for intestinal absorption
could become an option (perhaps even in the primary
form of hyperoxaluria as an additional measure)
[24,25]. Sidhu et al. [26] reported successful and
safe recolonization of O.formigenes in rats, leading to
a reduction of urinary oxalate excretion. Campieri
Fig. 1. Pathways of primary and secondary hyperoxaluria.
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et al. [21] treated ﬁve hyperoxaluric patients with a
preparation of lactic acid bacteria (Oxadrop) and
observed a signiﬁcant and persistent reduction in
urinary oxalate excretion over time.
Measures to increase the urinary solubility of
calcium oxalate
Most important is a high ﬂuid intake (3–4 l/day)
accompanied by the administration of either alkali
(Kþ/Naþ)–citrate [0.3–0.5meq (0.1–0.15 g)/kg body
weight/day] or orthophosphate (20–60mg/kg body
weight/day) [1].
Dialysis
No form of dialysis, not even the combination of
routine haemo- and peritoneal dialysis is able to keep
up with the endogenously produced oxalate, let alone
to reduce the body oxalate burden [27,28]. In fact, the
weekly oxalate elimination via haemo- or peritoneal
dialysis (6–9mmol/week/1.73m2 BSA) only equals
the endogenous oxalate production of 2–3 days [27].
Hence, intensiﬁed haemodialysis with ﬁve to six
sessions of 5 h/week and additionally nightly peritoneal
dialysis may be considered until transplantation is
performed. The higher the systemic oxalate burden the
more oxalate needs to be excreted after transplantation,
which further increases the risk of recurrence in the
transplant. Apart from young age (<5 years), a long
period on dialysis (>2 years) inevitably leading to
massive systemic oxalate deposition is a speciﬁc risk for
transplantation [9,29]. Hence, the dialysis period has to
be kept as short as possible.
Transplantation in primary hyperoxaluria
Isolated kidney transplantation is an option only for the
minority of patients responding well to pyridoxine
[1,30], and, perhaps, for patients with late onset of
ESRF (e.g. age >50 years). As a result of the high risk
of recurrence, combined liver/kidney transplantation is
the treatment modality of choice in Europe. Isolated
kidney transplantation is, however, still favoured in the
USA, preferably from living related donors [30]. The
medium term results are acceptable with actuarial
survival of 84% for patients and 51% for grafts after
6 years; however, graft survival at 10 years is only
35% [30].
As the metabolic defect in PH I is conﬁned to the
liver, combined liver/kidney transplantation will cure the
enzyme defect. Total hepatectomy of the patient’s own
and otherwise normal liver is necessary. Auxiliary liver
transplantation is no option, as the oxalate over-
production by the patient’s own liver would keep
the process ongoing [1]. More than 100 combined
liver/kidney transplantations have been performed in
Europe since 1984 with an actuarial survival at 5 years
(98 grafts in 93 patients) being 80% for patients and
71% for liver grafts. Renal function has remained
stable with creatinine clearance of 40–60ml/min
1.73m2 BSA after 5 years [1,29].
Additional haemodialysis or haemoﬁltration after
transplantation is only required if (renal) graft function
is inadequate. A steady high ﬂuid intake (3–4 l/day) and
medication to increase the urinary solubility of oxalate
are needed during the ﬁrst months because of the slow
mobilization of the accumulated body oxalate [1]. Not
only urinary oxalate excretion but also plasma oxalate
and plasma calcium oxalate saturation remain elevated
for several months or even years after successful
combined liver/kidney transplantation [1,15].
Pre-emptive (isolated) liver transplantation is an
option with the aim of avoiding ESRF [31]. However,
as liver transplantation is not harmless and the optimal
timing of transplantation is difﬁcult to determine due to
the unpredictable course of the disease, it is still not a
generally accepted method for patients with PH I.
Nevertheless, several patients with PH I not in renal
failure have been treated this way with reasonable
results [31]. Liver transplantation needs to be per-
formed as long as kidney function is still appropriate
(GFR >40ml/min, or even 50–70ml/min) [1,18].
Outlook
The time lag between the ﬁrst symptom and the
diagnosis often is far too long. Hence, the level of
suspicion needs to be lowered and the diagnostic
approach must be improved. Urinary oxalate excretion
has to be assessed in every patient with calcium oxalate
urolithiasis or nephrocalcinosis, and kidney stones
require appropriate analysis. Waiting for the next
lithotripsy session is by no means a preventive measure!
Various therapeutic approaches are available, the
ultimate goal being to prevent renal failure. Although
PH type I would be a good candidate for gene therapy
it is not yet applicable. Perhaps enzyme therapy
throughO.formigeneswill become a therapeutic option.
Note: early diagnosis and treatment are mandatory
in patients with PH to prevent a disastrous clinical
course.
Conﬂict of interest statement. B. Hoppe receives grant money from
Ixion Biotechnology Inc., Gainseville, FL, USA for oxalosacte
research.
References
1. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc
Nephrol 2001; 12: 1986–1993
2. Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A.
Diagnostic and therapeutic approaches in patients with
secondary hyperoxaluria. Front Biosci 2003; 8: e437–443
3. Wichmann G, Passauer J, Fischer R, Weise M, Gross P.
A young patient with end-stage renal disease, dyspnoea,
weakness, peripheral neuropathy and an unsuspected under-
lying disease. Nephrol Dial Transplant 2003; 18: 1670–1672
4. Hoppe B, Langman C. A United States survey on diagnosis,
treatment and outcome of patients with primary hyperoxaluria.
Pediatr Nephrol 2003; 18: 986–991
Diagnostic and therapeutic strategies in hyperoxaluria 41
5. Van Woerden CS, Groothoff JW, Wanders RJ, Davin JC,
Wijburg FA. Primary hyperoxaluria type 1 in the Netherlands:
prevalence and outcome. Nephrol Dial Transplant 2003; 18:
273–279
6. Danpure CJ, Jennings PR. Peroxisomal alanine:glyoxylate
aminotransferase deﬁciency in primary hyperoxaluria type I.
FEBS Lett 1986; 201: 20–24
7. Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP. The
gene encoding hydroxypyruvate reductase (GRHPR) is mutated
in patients with primary hyperoxaluria type II. Hum Mol Gen
1999; 8: 2063–2069
8. Cregeen DP, Rumsby G. Recent developments in our under-
standing of primary hyperoxaluria type 2. J Am Soc Nephrol
1999; 10: 348–350
9. Monico CG, Persson M, Ford GC, Rumsby G, Milliner DS.
Potential mechanisms of marked hyperoxaluria not due to
primary hyperoxaluria I or II. Kidney Int 2002; 62: 392–400
10. Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E.
Urinary oxalate excretion in urolithiasis and nephrocalcinosis.
Arch Dis Child 2000; 82: 322–326
11. Leumann EP, Dietl A, Matasovic A. Urinary oxalate and
glycolate excretion in healthy infants and children. Pediatr
Nephrol 1990; 4: 493–497
12. Laube N, Schneider A, Hesse A. A new approach to calculate
the risk of calcium oxalate crystallisation from unprepared
native urine. Urol Res 2003; 28: 274–280
13. Daudon M, Estepa L, Lacour B, Jungers P. Unusual
morphology of calcium oxalate calculi in primary hyperox-
aluria. J Nephrol 1998; 11 [Suppl 1]: 51–55
14. Ho¨now R, Hesse A. Interference-free sample preparation for
the determination of plasma oxalate analysed by HPLC-ER:
preliminary results from calcium oxalate stone-formers and non
stone-formers. Clin Chim Acta 2002; 318: 19–24
15. Hoppe B, Kemper MJ, Bo¨kenkamp A, Portale AA, Cohn RA,
Langman CB. Plasma calcium-oxalate supersaturation in
children with primary hyperoxaluria and end stage renal
disease. Kidney Int 1999; 56: 268–274
16. Marangella M, Petrarulo M, Vitale C et al. The primary
hyperoxalurias. Contrib Nephrol 2001; 136: 11–32
17. Hoppe B, Kemper MJ, Bo¨kenkamp A, Langman CB. Plasma
calcium-oxalate saturation in children with renal insufﬁciency
and in children with primary hyperoxaluria. Kidney Int 1998;
54: 921–925
18. Cochat P. Primary hyperoxaluria. Kidney Int 1999; 55:
2533–2547
19. Sidhu H, Schmidt ME, Cornelius JG et al. Direct correlation
between hyperoxaluria/oxalate stone disease and the absence
of the gastrointestinal tract-dwelling bacterium Oxalobacter
formigenes: possible prevention by gut recolonisation or
enzyme replacement therapy. J Am Soc Nephrol 1999; 14:
S334–340
20. Hokama S, Honma Y, Toma C, Ogawa Y. Oxalate
degrading Enterococcus faecalis. Microbiol Immunol 2000; 44:
235–240
21. Campieri C, Compieri M, Bertuzzi V et al. Reduction of
oxaluria after an oral course of lactic acid bacteria. Kidney Int
2001; 60: 1097–1105
22. Sidhu H, Hoppe B, Hesse A et al. Antibiotic induced loss of
the gut associated bacterium Oxalobacter formigenes: a risk
factor for hyperoxaluria in cystic ﬁbrosis patients. Lancet 1998;
352: 1026–1030
23. Hesse A, Schneeberger W, Engfeld S, von Unruh GE,
Sauerbruch T. Intestinal hyperabsorption of oxalate in calcium
oxalate stone formers: application of a new test with
[13C2]oxalate. J Am Soc Nephrol 1999; 10: S329–S333
24. Hoppe B, Hesse A, von Unruh G, Beck B, Schmidt H, Sidhu
H. Treatment with Oxalobacter formigenes: a new therapy in
patients with primary hyperoxaluria (PH)? Pediatr Nephrol
2003; 18: C15 (O12)
25. Hatch M, Freel RW. Renal and intestinal handling of
oxalate following oxalate loading in rats. Am J Nephrol 2003;
23: 18–26
26. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB. Rapid
reversal of hyperoxaluria in a rat model after probiotic
administration of Oxalobacter formigenes. J Urol 2001; 166:
1487–1491
27. Hoppe B, Graf D, Offner G et al. Oxalic acid elimination in
children with chronic renal failure: comparison between
hemodialysis and peritoneal dialysis. Pediatr Nephrol 1996;
10: 488–492
28. Marangella M, Petrarulo M, Vitale C et al. Serum calcium
oxalate saturation in patients on maintenance hemodialysis for
primary hyperoxaluria or oxalosis unrelated renal diseases.
Clin Sci 1991; 81: 483–490
29. Jamieson NV on behalf of the European PH I Transplantation
Study Group. The European primary hyperoxaluria type 1
transplant registry report on the results of combined liver/
kidney transplantation for primary hyperoxaluria 1984–1994.
Nephrol Dial Transplant 1995; 10 [Suppl 8]: 33–37
30. Saborio P, Scheinman JI. Transplantation for primary
hyperoxaluria in the United States. Kidney Int 1999; 56:
1094–1100
31. Nolkemper D, Kemper MJ, Burdelski M et al. Long-
term results of pre-emptive liver transplantation in primary
hyperoxaluria type 1. Pediatr Transplant 2000; 4: 177–
181
42 B. Hoppe and E. Leumann
